by Ruxolitinib Gains Recognition for At-home Treatment amid COVID-19 Crisis
In response to the public health emergency posed by the COVID-19 pandemic, National Health Service (NHS) England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with high risk of coronavirus. This has led to awareness about ruxolitinib, which is found to be effective in treating acute graft versus host disease (GvHD) patients who have not responded to steroids. Ruxolitinib is a tablet that can be consumed at home, which eliminates the need for a patient to visit hospital frequently and reduce the risk of contracting COVID-19.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111801
Companies in the acute graft versus host disease (GvHD) treatment market are increasing their output capacities and maintaining steady supply for ruxolitinib as an alternative treatment option, which is reducing the need to attend hospital unless adverse events occur.
Corticosteroids Associated with Adverse Effects, Dismal Patient Outcomes
Clinically significant GvHD occurs frequently in spite of prophylaxis, which has led to the demand for corticosteroids as the mainstay of frontline therapy. However, in many cases, these drugs can have severe adverse effects and outcomes are dismal in patients who historically have had limited treatment options. Such findings are affecting the growth of the global acute graft versus host disease (GvHD) treatment market. Hence, companies in the acute graft versus host disease (GvHD) treatment market are boosting their R&D capabilities to successfully manufacture drugs that can be administered in a multicenter environment.
Ruxolitinib Helps Overcome Steroid Resistance Found in GvHD Patients
Steroid resistance has been found in GvHD patients. This condition is difficult to treat and associated with a high mortality rate. In order to overcome these issues, companies in the acute graft versus host disease (GvHD) treatment market are boosting their output capacities for Ruxolitinib. This tablet holds promising potential as a treatment option for patients with steroid-refractory aGvHD after allogeneic hematopoietic stem cell transplantation.
Ruxolitinib tablet works by blocking the action of enzymes known as Janus kinases (JAKs) that are involved in the production and growth of blood cells & immune function. By blocking JAKs, ruxolitinib reduces the abnormal production of blood cells, which helps to reduce the symptoms of GvHD. This tablet helps to address the side effects linked with the consumption of steroids.
Manufacturers Increase Research in Orphan Drugs to Prevent GI Diseases
The gastrointestinal damage is a leading cause of death in patients with acute GvHD. The clinical stage biopharmaceutical company VectivBio Holding AG is gaining cognizance about this condition and has received the FDA orphan drug designation for apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases for the prevention of aGVHD. Companies in the acute graft versus host disease (GvHD) treatment market are gaining knowledge about such drug innovations and increasing their research capabilities.
Preclinical and clinical studies evaluating apraglutide & GLP-2 analogs in aGvHD indicate that apraglutide’s regenerative and anti-inflammatory effects on the GI tract may help to significantly reduce morbidity and mortality in patients suffering from intestinal GvHD.
Analysts’ Viewpoint
The ruxolitinib tablet is helping to avoid the need for urgent hospitalization in high-risk patients during the ongoing COVID-19 outbreak. The acute graft versus host disease (GvHD) treatment market is slated to clock a favorable CAGR of 8.6% during the forecast period. However, the high prevalence of steroid resistance has been found in GvHD patients. Hence, companies in the acute graft versus host disease (GvHD) treatment market should boost their production for ruxolitinib, which helps to improve outcomes in patient with steroid-refractory aGvHD after the allogeneic hematopoietic stem cell transplantation. As such, the acute graft versus host disease (GvHD) treatment market is expected to reach US$ 634.3 Mn by 2031.
Acute Graft Versus Host Disease (GvHD) Treatment Market: Overview
This report analyzes the current and future prospects of the global acute graft versus host disease (GvHD) treatment market. Focus on research & development and growth of the pharmaceutical industry are the key factors projected to fuel the growth of the global acute graft versus host disease (GvHD) treatment market during the forecast period.
The report provides an elaborate executive summary, which comprises a snapshot of the various segments of the global acute graft versus host disease (GvHD) treatment market. The report also provides information and data analysis of the global acute graft versus host disease (GvHD) treatment market about segments based on drug class, route of administration, distribution channel, and region.
The overview section of the report provides detailed qualitative analysis of drivers and restraints affecting the global acute graft versus host disease (GvHD) treatment market, along with opportunities in the global market
Additionally, the global acute graft versus host disease (GvHD) treatment market report includes company profiles and competitive matrix, which provide data about their businesses, product portfolios, and competitive landscape in the global acute graft versus host disease (GvHD) treatment market
The report includes data analysis on the global acute graft versus host disease (GvHD) treatment market attractiveness by region and segments
The last section of the report provides quantitative and qualitative analysis on market share of key players operating in the global acute graft versus host disease (GvHD) treatment market. It elaborates on the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global acute graft versus host disease (GvHD) treatment market.
Acute Graft Versus Host Disease (GvHD) Treatment Market: Key Segments
In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others
Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous
In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is likely to dominate the global acute graft versus host disease (GvHD) treatment market during the forecast period.
The market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year.
Acute Graft Versus Host Disease (GvHD) Treatment Market: Regional Outlook
In terms of region, the global acute graft versus host disease (GvHD) treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa)
The report provides market size and forecast for each region and country/sub-region from 2017 to 2031. Compound annual growth rate (CAGR) of each of these regions and countries have also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year. The acute graft versus host disease (GvHD) treatment market study also covers the competitive scenario in these regions.
Companies Mentioned in Report
Key players in the global acute graft versus host disease (GvHD) treatment market have been profiled based on key aspects such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
Major companies profiled in the global acute graft versus host disease (GvHD) treatment market report are
- Bristol-Myers Squibb
- Novartis AG
- Mesoblast Ltd.
- Equillium, Inc.
- Cynata Therapeutics Limited
- MaaT Pharma
- Incyte Corporation
- Xenikos B.V.
- Merck & Co. (OncoImmune, Inc.)
- medac GmbH
- CSL Limited
Key Questions Answered in Acute Graft Versus Host Disease (GvHD) Treatment Market Report
- How does the development of acute graft versus host disease (GvHD) treatment provide scope of growth in the global acute graft versus host disease (GvHD) treatment market?
- How alliances and partnerships between players are widening the scope of new line of therapies for acute graft versus host disease (GvHD) treatment?
- What are the revenue share projections of key segments under various criteria in the acute graft versus host disease (GvHD) treatment market during the forecast period?
- Which segment is likely to register highest revenue until the end of the forecast period in 2031?
- How is the evolving healthcare system in developing countries in Asia Pacific making an impact on the overall acute graft versus host disease (GvHD) treatment market?
Acute Graft Versus Host Disease (GvHD) Treatment Market – Segmentation
Drug Class
- Corticosteroids
- Immunosuppressive Agents
- Biological Therapy
- Kinase Inhibitors
- Monoclonal Antibody
- Mesenchymal Stem Cell (MSC)
- Others
Route of Administration
- Oral
- Topical
- Intravenous
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region
North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111801/2900
